Predict your next investment

Corporation
HEALTHCARE
sandoz.com

See what CB Insights has to offer

Founded Year

1886

Stage

Acquired | Acquired

About Sandoz

Sandoz, a Novartis company, is a global provider of generic pharmaceuticals and biosimilars, driving sustainable access to high-quality healthcare. Sandoz supplies a broad range of affordable, primarily off-patent products to patients and customers around the globe.

Sandoz Headquarter Location

Industriestrasse 25

Holzkirchen, D-83607,

Germany

+49 (0) 8024 476-0

Latest Sandoz News

Amgen stalls Samsung's Enbrel biosim until 2029 in 2nd patent win of the year

Dec 1, 2021

Amgen's update marks the second setback for an Enbrel biosimilar this year. (Amgen) Amgen breathed a sigh of relief this summer when the Supreme Court declined to take up a Sandoz patent dispute challenging its anti-inflammatory blockbuster Enbrel. Now, the California drugmaker has warded off a second would-be rival, securing monopoly sales for many years to come. The U.S. District Court for the District of New Jersey sided with Amgen, Roche and Immunex in their bid to keep Samsung Bioepis’ Enbrel biosimilar, Eticovo, off the U.S. market until nearly the end of the decade. In documents filed last month, the court held that Samsung would infringe two Enbrel patents if it tried to sell its copycat before 2029, when the patents expire. The update marks the second patent setback for an Enbrel biosimilar this year. The first came for Erelzi, made by Novartis’ generics unit Sandoz. In May, the Supreme Court shot down Sandoz’s petition to review earlier decisions that had favored Amgen. As in Samsung's case, that decision pushed Sandoz's biosimilar launch to 2029 at the earliest. With the latest judgment, Samsung Bioepis won’t be able to make, sell or import its drug in the U.S. before 2029. The court also ordered Samsung to “immediately destroy any remaining Bioepis etanercept product that has been imported into the United States.” Etanercept is the generic name for Enbrel, a tumor necrosis factor-inhibitor used to treat rheumatoid arthritis, ankylosing spondylitis and more.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Sandoz

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Sandoz is included in 1 Expert Collection, including Psychedelics.

P

Psychedelics

231 items

Sandoz Patents

Sandoz has filed 175 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • Dosage forms
  • Pharmaceutical industry
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/25/2017

9/21/2021

Pharmaceutical industry, Penicillins, Antibiotics, Sedatives, Amines

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

8/25/2017

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

9/21/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Pharmaceutical industry, Penicillins, Antibiotics, Sedatives, Amines

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.